1
|
Xu Y, Li M, Lin M, Cui D, Xie J. Glutaminolysis of CD4 + T Cells: A Potential Therapeutic Target in Viral Diseases. J Inflamm Res 2024; 17:603-616. [PMID: 38318243 PMCID: PMC10840576 DOI: 10.2147/jir.s443482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Accepted: 01/13/2024] [Indexed: 02/07/2024] Open
Abstract
CD4+ T cells play a critical role in the pathogenesis of viral diseases, which are activated by the internal metabolic pathways encountering with viral antigens. Glutaminolysis converts glutamine into tricarboxylic acid (TCA) circulating metabolites by α-ketoglutaric acid, which is essential for the proliferation and differentiation of CD4+ T cells and plays a central role in providing the energy and structural components needed for viral replication after the virus hijacks the host cell. Changes in glutaminolysis in CD4+ T cells are accompanied by changes in the viral status of the host cell due to competition for glutamine between immune cells and host cells. More recently, attempts have been made to treat tumours, autoimmune diseases, and viral diseases by altering the breakdown of glutamine in T cells. In this review, we will discuss the current knowledge of glutaminolysis in the CD4+ T cell subsets from viral diseases, not only increasing our understanding of immunometabolism but also providing a new perspective for therapeutic target in viral diseases.
Collapse
Affiliation(s)
- Yushan Xu
- Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, People’s Republic of China
| | - Miaomiao Li
- Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, People’s Republic of China
| | - Mengjiao Lin
- Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, People’s Republic of China
| | - Dawei Cui
- Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, People’s Republic of China
| | - Jue Xie
- Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, People’s Republic of China
| |
Collapse
|
3
|
Xing K, Che Y, Wang Z, Yuan S, Wu Q, Shi F, Chen Y, Shen X, Zhong X, Xie X, Zhu Q, Li X. Chitosan nanoparticles encapsulated with BEZ235 prevent acute rejection in mouse heart transplantation. Int Immunopharmacol 2023; 124:110922. [PMID: 37699303 DOI: 10.1016/j.intimp.2023.110922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2023] [Revised: 09/04/2023] [Accepted: 09/07/2023] [Indexed: 09/14/2023]
Abstract
Acute rejection may manifest following heart transplantation, despite the implementation of relatively well-established immunosuppression protocols. The significance of the mTOR signaling pathway in rejection is widely acknowledged. BEZ235, a second-generation mTOR inhibitor with dual inhibitory effects on PI3K and mTOR, holds promise for clinical applications. This study developed a nanodelivery system, BEZ235@NP, to facilitate the intracellular delivery of BEZ235, which enhances efficacy and reduces adverse effects by improving the poor solubility of BEZ235. In the complete MHCII-mismatched model, BEZ235@NP significantly prolonged cardiac allografts survival compared to free BEZ235, which was attributed to more effective suppression of effector T cell activation and promotion of greater expansion of Tregs. These nanoparticles demonstrated excellent biosafety and exhibited no short-term biotoxicity upon investigation. To elucidate the mechanism, primary T cells were isolated from the spleen and it was observed that BEZ235@NP treatment resulted in the arrest of these cells in the G0/G1 phase. As indicated by Western blot analysis, BEZ235@NP substantially reduced mTOR phosphorylation. This, in turn, suppressed downstream pathways and ultimately exerted an anti-proliferative and anti-activating effect on cells. Furthermore, it was observed that inhibition of the mTOR pathway stimulated T-cell autophagy. In conclusion, the strategy of intracellular delivery of BEZ235 presents promising applications for the treatment of acute rejection.
Collapse
Affiliation(s)
- Kai Xing
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Yanjia Che
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Zhiwei Wang
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China.
| | - Shun Yuan
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Qi Wu
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Feng Shi
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Yuanyang Chen
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Xiaoyan Shen
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Xiaohan Zhong
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Xiaoping Xie
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Qingyi Zhu
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| | - Xu Li
- Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Cardiovascular Surgery Laboratory, Renmin Hospital of Wuhan University, District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China; Central Laboratory, Renmin Hospital of Wuhan University. District No. 99, Zhang Road, Wuhan 430060, Hubei, PR China
| |
Collapse
|
4
|
Koshida K, Ito M, Yakabe K, Takahashi Y, Tai Y, Akasako R, Kimizuka T, Takano S, Sakamoto N, Haniuda K, Ogawa S, Kimura S, Kim YG, Hase K, Harada Y. Dysfunction of Foxp3 + Regulatory T Cells Induces Dysbiosis of Gut Microbiota via Aberrant Binding of Immunoglobulins to Microbes in the Intestinal Lumen. Int J Mol Sci 2023; 24:ijms24108549. [PMID: 37239894 DOI: 10.3390/ijms24108549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 05/08/2023] [Accepted: 05/08/2023] [Indexed: 05/28/2023] Open
Abstract
Foxp3+ regulatory T (Treg) cells prevent excessive immune responses against dietary antigens and commensal bacteria in the intestine. Moreover, Treg cells contribute to the establishment of a symbiotic relationship between the host and gut microbes, partly through immunoglobulin A. However, the mechanism by which Treg cell dysfunction disturbs the balanced intestinal microbiota remains unclear. In this study, we used Foxp3 conditional knockout mice to conditionally ablate the Foxp3 gene in adult mice and examine the relationship between Treg cells and intestinal bacterial communities. Deletion of Foxp3 reduced the relative abundance of Clostridia, suggesting that Treg cells have a role in maintaining Treg-inducing microbes. Additionally, the knockout increased the levels of fecal immunoglobulins and immunoglobulin-coated bacteria. This increase was due to immunoglobulin leakage into the gut lumen as a result of loss of mucosal integrity, which is dependent on the gut microbiota. Our findings suggest that Treg cell dysfunction leads to gut dysbiosis via aberrant antibody binding to the intestinal microbes.
Collapse
Affiliation(s)
- Kouhei Koshida
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
| | - Mitsuki Ito
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| | - Kyosuke Yakabe
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
- Research Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
| | - Yoshimitsu Takahashi
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| | - Yuki Tai
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| | - Ryouhei Akasako
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| | - Tatsuki Kimizuka
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
- Research Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
| | - Shunsuke Takano
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
| | - Natsumi Sakamoto
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| | - Kei Haniuda
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Shuhei Ogawa
- Division of Integrated Research, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda 278-0022, Japan
| | - Shunsuke Kimura
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
| | - Yun-Gi Kim
- Research Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
| | - Koji Hase
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo 105-8512, Japan
- The Institute of Fermentation Sciences (IFeS), Faculty of Food and Agricultural Sciences, Fukushima University, Fukushima 960-1296, Japan
| | - Yohsuke Harada
- Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| |
Collapse
|